Genocea Biosciences, Inc. (GNCA)


-0.00 (-85.71%)
Symbol GNCA
Price $0.0001
Beta 0.000
Volume Avg. 0.08M
Market Cap -
Shares () -
52 Week Range 1.0E-4-1.45
1y Target Est -
DCF Unlevered GNCA DCF ->
DCF Levered GNCA LDCF ->
ROE -85.53% Strong Sell
ROA -27.55% Sell
Operating Margin -
Debt / Equity 41.12% Neutral
P/E -
P/B 0 Neutral


Consensus EPS

Upgrades & Downgrades

Latest GNCA news

Mr. William Clark
NASDAQ Capital Market

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.